Early R&D poses many questions and challenges when determining if a biotherapeutic enters the portfolio, and if so, what are its design characteristics? Some of the questions include an assessment of unmet medical need, competitive landscape,
intellectual property, reimbursement, and difficulties of developability. Applied BioMath Assess is a new, interactive, web-based application that helps project leaders, protein engineers and chemists, and modelers assess the difficulties
and risks in developing a therapeutic very early-on in a project. In this webinar, we will demonstrate how project teams are using Applied BioMath Assess to answer key R&D questions, such as:
- How does affinity impact target inhibition? Will it impact TMDD if membrane bound?
- How does dosing interval impact success criteria?
- How does target expression, especially in the site of action, impact design criteria?
- How to think about therapeutic index?
Learn how Applied BioMath Assess can help you design best-in-class properties, get to clinical candidate selection faster, and terminate infeasible projects earlier.
John M. Burke, PhD
Co-founder, President and CEO
Dr. John Burke is a Co-Founder and the President and CEO of Applied BioMath, LLC. He has over 24 years of mathematical modeling, analysis, and simulation experience in life sciences and mathematical biology, and over 18 years’ experience
assisting pharmaceutical and biotechnology research, development, and clinical trial support.
Prior to co-founding Applied BioMath, John served as the head of Systems Biology at Boehringer Ingelheim, where he was responsible for starting, implementing, scaling, and managing the strategy, portfolio, and efforts of Boehringer Ingelheim’s
systems pharmacology initiative. Dr. Burke also worked at Merrimack Pharmaceuticals, where he supported multiple biologics projects.
He received his PhD in Mathematics from Arizona State University (ASU) in 2003. He received his BS and MS in Applied Mathematics from University of Massachusetts Lowell, where he is presently an Adjunct Professor at the Mathematics Department.
Following his graduate work, Dr Burke joined Douglas Lauffenberger’s lab, in the Biological Engineering Dept, at the Massachusetts Institute of Technology as a Postdoctoral Fellow, and later as a Sr Fellow. After MIT, he joined Peter
Sorger’s lab, in the Systems Biology Department, at Harvard Medical School, as Co-scientific Director of the Cell Decision Process, an NIH Center of Excellence. While at MIT and HMS, he provided systems math modeling and simulation consulting
and advice for numerous biotechs and pharma, including AstraZeneca, Pfizer, Momenta, and other companies.
Cost: No Cost!